CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07225439
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:00.205319+00:00
Published At: 2025-11-06T00:00:00+00:00
Record Updated At: 2025-11-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non Hodgkin Lymphoma", "B-cell Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B Cell Lymphoma", "Follicular Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-06"
protocolSection.identificationModule.nctId: "NCT07225439"
protocolSection.identificationModule.officialTitle: "Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.